Clinical Trial Update: Safety and Efficacy of Xalkori ROS1

View source ↗

Summary

This clinical trial update summarizes safety and efficacy findings for crizotinib (Xalkori) in patients with ROS1-rearranged non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Xalkori (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: Non-small Cell Lung Cancer | Status: ACTIVE_NOT_RECRUITING